| || Work location: Varna (Burgas and Rouse could also be considered)
Manage regional key accounts & key ambulatory HCPs to ensure successful product launch and continued promotional activities.
•Develops & executes effective strategy plan for collaboration with key accounts.
•Integrates promotional and educational activities and services, as required in order to secure and maintain account support.
•Demonstrates a broad and deep knowledge of technical/medical aspects of MS business, effective consultative and relationship management techniques.
•Is considered by customers and others in the organization as being expert on Novartis products and therapeutics, as well as being knowledgeable regarding competitive products, personnel, marketing/key account management strategies and tactics within the assigned accounts.
•Works in team and coordinates with the Product Specialist/Brand Manager the field activities as well as provides input during the brand marketing strategies (IPS, Strat Plan, Budgeting, Tactical Planning).
•Develops and manages critical relationships with key specialists in assigned key accounts – commissions, as well as covers a target of top selected ambulatory specialists, for a given geographic area
•Manages patient flow from ambulatory to commissions, interacts with RHIF to facilitate patient flow and successfully manage key administrative processes.
•Observe strictly any and all applicable internal and external regulations, acts and procedures
•Responsible for proper and compliant reporting of Adverse Events in order to fulfill all regulatory requirements and ethical obligations including timely forwarding of all spontaneous reports to local Drug Safety Responsible.
•Comply with the GxP quality requirements applicable to his/her area of responsibility, incl. but not limited to proper reporting of adverse events and customer complaints, samples handling as well as any incident that may adversely affect the quality, safety, identity, strength, purity, availability or efficacy of a commercial product or clinical trial material and/or may compromise the Novartis Quality System and the global Novartis reputation.